Published in Psychopharmacology (Berl) on April 01, 2014
The adolescent brain and age-related behavioral manifestations. Neurosci Biobehav Rev (2000) 17.59
Making memories: brain activity that predicts how well visual experience will be remembered. Science (1998) 10.73
Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science (1983) 9.41
A new one-trial test for neurobiological studies of memory in rats. 1: Behavioral data. Behav Brain Res (1988) 7.29
Structural and functional brain development and its relation to cognitive development. Biol Psychol (2000) 5.40
Episodic memory, amnesia, and the hippocampal-anterior thalamic axis. Behav Brain Sci (1999) 5.12
Neuroinflammation in Parkinson's disease: a target for neuroprotection? Lancet Neurol (2009) 4.88
Remembering episodes: a selective role for the hippocampus during retrieval. Nat Neurosci (2000) 4.58
Prefrontal executive and cognitive functions in rodents: neural and neurochemical substrates. Neurosci Biobehav Rev (2004) 4.38
Pubertal hormones organize the adolescent brain and behavior. Front Neuroendocrinol (2005) 3.78
Parkinson's disorder, psychomotor problems and dopaminergic neurotoxicity in recreational ecstasy/MDMA users. Psychopharmacology (Berl) (2003) 2.47
Involvement of the prelimbic-infralimbic areas of the rodent prefrontal cortex in behavioral flexibility for place and response learning. J Neurosci (1999) 2.45
Interleukin-6 facilitates lipopolysaccharide-induced disruption in working memory and expression of other proinflammatory cytokines in hippocampal neuronal cell layers. J Neurosci (2006) 2.22
Memory impairment in abstinent MDMA ("Ecstasy") users. Neurology (1998) 2.00
Basal-ganglia 'projections' to the prefrontal cortex of the primate. Cereb Cortex (2002) 1.98
The aging hippocampus: cognitive, biochemical and structural findings. Cereb Cortex (2003) 1.98
Patterns of simultaneous polysubstance use in drug using university students. Hum Psychopharmacol (2006) 1.78
Neurotoxicity of substituted amphetamines: molecular and cellular mechanisms. Neurotox Res (2007) 1.77
Molecular and cellular mechanisms of ecstasy-induced neurotoxicity: an overview. Mol Neurobiol (2009) 1.42
What are the specific vs. generalized effects of drugs of abuse on neuropsychological performance? Neurosci Biobehav Rev (2010) 1.33
Effect of lesion of cortical dopamine terminals on subcortical dopamine receptors in rats. Nature (1980) 1.31
Morphological evidence for a dopaminergic terminal field in the hippocampal formation of young and adult rat. Neuroscience (1985) 1.28
Role for excitatory amino acids in methamphetamine-induced nigrostriatal dopaminergic toxicity. Science (1989) 1.24
Incidence of Parkinson's disease among hospital patients with methamphetamine-use disorders. Mov Disord (2010) 1.20
Recreational Ecstasy/MDMA, the serotonin syndrome, and serotonergic neurotoxicity. Pharmacol Biochem Behav (2002) 1.19
Prefrontal hypoactivation during cognitive control in early abstinent methamphetamine-dependent subjects. Psychiatry Res (2011) 1.17
Diverse microglial responses after intrahippocampal administration of lipopolysaccharide. Glia (2006) 1.16
Bone marrow-derived microglia contribute to the neuroinflammatory response and express iNOS in the MPTP mouse model of Parkinson's disease. Neurobiol Dis (2005) 1.12
The reality of psychomotor problems, and the possibility of Parkinson's disorder, in some recreational ecstasy/MDMA users: a rejoinder to Sumnall et al. (2003). Psychopharmacology (Berl) (2003) 1.07
Ecstasy (MDMA) effects upon mood and cognition: before, during and after a Saturday night dance. Psychopharmacology (Berl) (1998) 1.05
Methamphetamine-induced neuroinflammation and neuronal dysfunction in the mice hippocampus: preventive effect of indomethacin. Eur J Neurosci (2010) 1.03
Behavioral evidence for a modulating role of sigma ligands in memory processes. I. Attenuation of dizocilpine (MK-801)-induced amnesia. Brain Res (1994) 1.02
3,4-Methylenedioxymethamphetamine increases interleukin-1beta levels and activates microglia in rat brain: studies on the relationship with acute hyperthermia and 5-HT depletion. J Neurochem (2004) 1.02
Amphetamine exposure is elevated in Parkinson's disease. Neurotoxicology (2006) 1.02
Revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease--resemblance to the effect of amphetamine drugs of abuse. Free Radic Biol Med (2012) 1.01
Relationships between the prefrontal cortex and the basal ganglia in the rat: physiology of the cortico-nigral circuits. J Neurosci (1999) 1.01
Persistent MDMA-induced dopaminergic neurotoxicity in the striatum and substantia nigra of mice. J Neurochem (2008) 0.99
Modulatory role of cyclooxygenase inhibitors in aging- and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav Brain Res (2002) 0.99
Psychosocial profiles of older adolescent MDMA users. Drug Alcohol Depend (2004) 0.96
Neurotoxicity of methamphetamine and 3,4-methylenedioxymethamphetamine. Life Sci (2013) 0.95
Preliminary evidence of hippocampal dysfunction in adolescent MDMA ("ecstasy") users: possible relationship to neurotoxic effects. Psychopharmacology (Berl) (2003) 0.95
Role of interleukin-6 in lipopolysaccharide-induced brain injury and behavioral dysfunction in neonatal rats. Neuroscience (2006) 0.95
Memory-related hippocampal dysfunction in poly-drug ecstasy (3,4-methylenedioxymethamphetamine) users. Psychopharmacology (Berl) (2005) 0.93
Dopamine-dependent tuning of striatal inhibitory synaptogenesis. J Neurosci (2010) 0.92
The consequences of 3,4-methylenedioxymethamphetamine induced CYP2D6 inhibition in humans. J Clin Psychopharmacol (2008) 0.92
Memory-related hippocampal functioning in ecstasy and amphetamine users: a prospective fMRI study. Psychopharmacology (Berl) (2012) 0.91
Functional MRI study of working memory in MDMA users. Psychopharmacology (Berl) (2004) 0.90
Memory deficit and reduced anxiety in young adult rats given repeated intermittent MDMA treatment during the periadolescent period. Pharmacol Biochem Behav (2004) 0.89
Prospective memory deficits in Ecstasy users: effects of longer ongoing task delay interval. J Clin Exp Neuropsychol (2011) 0.87
Cytochrome P450 2D6 enzyme neuroprotects against 1-methyl-4-phenylpyridinium toxicity in SH-SY5Y neuronal cells. Eur J Neurosci (2010) 0.86
Neural mechanisms of working memory in ecstasy (MDMA) users who continue or discontinue ecstasy and amphetamine use: evidence from an 18-month longitudinal functional magnetic resonance imaging study. Biol Psychiatry (2004) 0.86
Neurotoxicity and persistent cognitive deficits induced by combined MDMA and alcohol exposure in adolescent rats. Addict Biol (2010) 0.86
Enhanced tau phosphorylation in the hippocampus of mice treated with 3,4-methylenedioxymethamphetamine ("Ecstasy"). J Neurosci (2008) 0.85
Effect of 3,4-methylendioxymethamphetamine (MDMA, "ecstasy") on dopamine transmission in the nucleus accumbens shell and core. Brain Res (2005) 0.84
MDMA and 5-HT neurotoxicity: the empirical evidence for its adverse effects in humans - no need for translation. Br J Pharmacol (2012) 0.84
Parkinson's disease and inflammatory changes. Neurotox Res (2003) 0.84
Sex-dependent long-term effects of adolescent exposure to THC and/or MDMA on neuroinflammation and serotoninergic and cannabinoid systems in rats. Br J Pharmacol (2014) 0.84
The effect of amphetamine analogs on cleaved microtubule-associated protein-tau formation in the rat brain. Neuroscience (2006) 0.84
Reduced calcium/calmodulin-dependent protein kinase II activity in the hippocampus is associated with impaired cognitive function in MPTP-treated mice. J Neurochem (2012) 0.84
Comparative aromatic hydroxylation and N-demethylation of MPTP neurotoxin and its analogs, N-methylated beta-carboline and isoquinoline alkaloids, by human cytochrome P450 2D6. Toxicol Appl Pharmacol (2006) 0.83
MPTP-induced dopaminergic degeneration and deficits in object recognition in rats are accompanied by neuroinflammation in the hippocampus. Pharmacol Biochem Behav (2010) 0.83
Cognitive changes in mice following moderate MPTP exposure. Brain Res Bull (1998) 0.83
Chronic methamphetamine exposure produces a delayed, long-lasting memory deficit. Synapse (2013) 0.83
Verbal memory deficits are correlated with prefrontal hypometabolism in (18)FDG PET of recreational MDMA users. PLoS One (2013) 0.83
Methylenedioxymethamphetamine inhibits mitochondrial complex I activity in mice: a possible mechanism underlying neurotoxicity. Br J Pharmacol (2010) 0.83
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol (2013) 0.82
The role of nitric oxide in dizocilpine-induced impairment of spontaneous alternation behavior in mice. J Pharmacol Exp Ther (1996) 0.82
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
MPTP lesion causes neuroinflammation and deficits in object recognition in Wistar rats. Behav Neurosci (2009) 0.81
Chronic activation of the D2 dopamine autoreceptor inhibits synaptogenesis in mesencephalic dopaminergic neurons in vitro. Eur J Neurosci (2008) 0.81
Caffeine promotes hyperthermia and serotonergic loss following co-administration of the substituted amphetamines, MDMA ("Ecstasy") and MDA ("Love"). Neuropharmacology (2005) 0.81
Memory impairment and hippocampus specific protein oxidation induced by ethanol intake and 3, 4-methylenedioxymethamphetamine (MDMA) in mice. J Neurochem (2013) 0.81
Organization of central nervous system dopaminergic pathways. J Neural Transm Suppl (1986) 0.80
Behavioural and neuroinflammatory effects of the combination of binge ethanol and MDMA in mice. Psychopharmacology (Berl) (2011) 0.80
Young adults' trajectories of Ecstasy use: a population based study. Addict Behav (2013) 0.80
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp Brain Res (2007) 0.80
Mice with decreased cerebral dopamine function following a neurotoxic dose of MDMA (3,4-methylenedioxymethamphetamine, "Ecstasy") exhibit increased ethanol consumption and preference. J Pharmacol Exp Ther (2007) 0.79
High concentrations of MDMA ('ecstasy') and its metabolite MDA inhibit calcium influx and depolarization-evoked vesicular dopamine release in PC12 cells. Neuropharmacology (2011) 0.79
Acquisition and reinstatement of MDMA-induced conditioned place preference in mice pre-treated with MDMA or cocaine during adolescence. Addict Biol (2009) 0.79
Parkinsonism in patients with a history of amphetamine exposure. Mov Disord (2010) 0.78
Caffeine induces a profound and persistent tachycardia in response to MDMA ("Ecstasy") administration. Eur J Pharmacol (2006) 0.78
Pro-oxidant effects of Ecstasy and its metabolites in mouse brain synaptosomes. Br J Pharmacol (2012) 0.77
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem (2012) 0.76
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord (2013) 0.76
MPP+ produces progressive neuronal degeneration which is mediated by oxidative stress. Exp Neurol (1997) 0.76
Tropisetron, a 5-HT(3) receptor antagonist, enhances object exploration in intact female rats. Behav Pharmacol (2012) 0.75
Localization of MPP+ binding sites in the brain of various mammalian species. J Neural Transm Park Dis Dement Sect (1992) 0.75
Targeting adenosine A2A receptors in Parkinson's disease. Trends Neurosci (2006) 2.14
Dyskinetic potential of dopamine agonists is associated with different striatonigral/striatopallidal zif-268 expression. Exp Neurol (2010) 1.44
Blockade of A2A receptors plus l-DOPA after nigrostriatal lesion results in GAD67 mRNA changes different from l-DOPA alone in the rat globus pallidus and substantia nigra reticulata. Exp Neurol (2003) 1.38
Birth asphyxia as the major complication in newborns: moving towards improved individual outcomes by prediction, targeted prevention and tailored medical care. EPMA J (2011) 1.17
The 6-hydroxydopamine model of Parkinson's disease. Neurotox Res (2007) 1.09
New therapies for the treatment of Parkinson's disease: adenosine A2A receptor antagonists. Life Sci (2005) 1.02
Inactivation of neuronal forebrain A receptors protects dopaminergic neurons in a mouse model of Parkinson's disease. J Neurochem (2009) 0.98
Pharmacological characterization of 50-kHz ultrasonic vocalizations in rats: comparison of the effects of different psychoactive drugs and relevance in drug-induced reward. Neuropharmacology (2012) 0.95
Anxiolytic-like effects of N,N-dialkyl-2-phenylindol-3-ylglyoxylamides by modulation of translocator protein promoting neurosteroid biosynthesis. J Med Chem (2008) 0.93
Modification of adenosine extracellular levels and adenosine A(2A) receptor mRNA by dopamine denervation. Eur J Pharmacol (2002) 0.92
Late-onset Parkinsonism in NFκB/c-Rel-deficient mice. Brain (2012) 0.91
EEG modifications in the cortex and striatum after dopaminergic priming in the 6-hydroxydopamine rat model of Parkinson's disease. Brain Res (2003) 0.88
Synthesis of ibuprofen heterocyclic amides and investigation of their analgesic and toxicological properties. Eur J Med Chem (2003) 0.87
Perinatal asphyxia: current status and approaches towards neuroprotective strategies, with focus on sentinel proteins. Neurotox Res (2010) 0.87
Differential regulation of GAD67, enkephalin and dynorphin mRNAs by chronic-intermittent L-dopa and A2A receptor blockade plus L-dopa in dopamine-denervated rats. Synapse (2002) 0.87
A new ethyladenine antagonist of adenosine A(2A) receptors: behavioral and biochemical characterization as an antiparkinsonian drug. Neuropharmacology (2009) 0.85
Role of neuroactive steroid allopregnanolone in antipsychotic-like action of olanzapine in rodents. Neuropsychopharmacology (2004) 0.85
Blockade of adenosine A2A receptors antagonizes parkinsonian tremor in the rat tacrine model by an action on specific striatal regions. Exp Neurol (2004) 0.84
Motor stimulant effects of the adenosine A(2A) receptor antagonist SCH 58261 do not develop tolerance after repeated treatments in 6-hydroxydopamine-lesioned rats. Synapse (2001) 0.84
Rehabilitation improves dyskinesias in Parkinsonian patients: a pilot study comparing two different rehabilitative treatments. NeuroRehabilitation (2012) 0.84
Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat. Synapse (2008) 0.83
Adenosine A2A receptor antagonists improve deficits in initiation of movement and sensory motor integration in the unilateral 6-hydroxydopamine rat model of Parkinson's disease. Synapse (2007) 0.83
Synthesis of new 2-arylamino-6-trifluoromethylpyridine-3-carboxylic acid derivatives and investigation of their analgesic activity. Bioorg Med Chem (2004) 0.82
Assessment of symptomatic and neuroprotective efficacy of Mucuna pruriens seed extract in rodent model of Parkinson's disease. Neurotox Res (2009) 0.82
Sensitization to caffeine and cross-sensitization to amphetamine: influence of individual response to caffeine. Behav Brain Res (2006) 0.82
Strain dependence of adolescent Cannabis influence on heroin reward and mesolimbic dopamine transmission in adult Lewis and Fischer 344 rats. Addict Biol (2013) 0.82
Performance of movement in hemiparkinsonian rats influences the modifications induced by dopamine agonists in striatal efferent dynorphinergic neurons. Exp Neurol (2013) 0.82
Caffeine enhances astroglia and microglia reactivity induced by 3,4-methylenedioxymethamphetamine ('ecstasy') in mouse brain. Neurotox Res (2009) 0.81
Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy. EPMA J (2010) 0.81
Characterization of the antiparkinsonian effects of the new adenosine A2A receptor antagonist ST1535: acute and subchronic studies in rats. Eur J Pharmacol (2007) 0.81
Adenosine A2A receptor antagonism increases striatal glutamate outflow in dopamine-denervated rats. Eur J Pharmacol (2003) 0.81
Impulse control disorders and dopamine dysregulation syndrome associated with dopamine agonist therapy in Parkinson's disease. Behav Pharmacol (2009) 0.81
Nicotinamide prevents the long-term effects of perinatal asphyxia on apoptosis, non-spatial working memory and anxiety in rats. Exp Brain Res (2009) 0.81
Dyskinesia in Parkinson's disease: mechanisms and current non-pharmacological interventions. J Neurochem (2014) 0.81
How reliable is the behavioural evaluation of dyskinesia in animal models of Parkinson's disease? Behav Pharmacol (2006) 0.80
Anxiolytic properties of a 2-phenylindolglyoxylamide TSPO ligand: Stimulation of in vitro neurosteroid production affecting GABAA receptor activity. Psychoneuroendocrinology (2010) 0.80
Potentiation of amphetamine-mediated responses in caffeine-sensitized rats involves modifications in A2A receptors and zif-268 mRNAs in striatal neurons. J Neurochem (2006) 0.80
Acute perinatal asphyxia impairs non-spatial memory and alters motor coordination in adult male rats. Exp Brain Res (2007) 0.80
Intensive rehabilitation treatment in parkinsonian patients with dyskinesias: a preliminary study with 6-month followup. Parkinsons Dis (2012) 0.80
Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases. Neurotherapeutics (2009) 0.80
A critical evaluation of behavioral rodent models of motor impairment used for screening of antiparkinsonian activity: The case of adenosine A(2A) receptor antagonists. Neurotox Res (2013) 0.80
Adenosine A2A and dopamine receptor interactions in basal ganglia of dopamine denervated rats. Neurology (2003) 0.80
Subchronic caffeine exposure induces sensitization to caffeine and cross-sensitization to amphetamine ipsilateral turning behavior independent from dopamine release. Neuropsychopharmacology (2003) 0.80
New adenosine A2A receptor antagonists: actions on Parkinson's disease models. Eur J Pharmacol (2005) 0.79
Neuroprotective and anti-inflammatory effects of the adenosine A(2A) receptor antagonist ST1535 in a MPTP mouse model of Parkinson's disease. Synapse (2011) 0.79
Involvement of globus pallidus in the antiparkinsonian effects of adenosine A(2A) receptor antagonists. Exp Neurol (2006) 0.79
Alteration in the progression of dopamine neuron degeneration: may caffeine offer new perspective? Exp Neurol (2012) 0.78
Role of movement in long-term basal ganglia changes: implications for abnormal motor responses. Front Comput Neurosci (2013) 0.78
Methylxanthines and drug dependence: a focus on interactions with substances of abuse. Handb Exp Pharmacol (2011) 0.78
Dopamine and adenosine receptor interaction as basis for the treatment of Parkinson's disease. J Neurol Sci (2006) 0.77
Expression of dyskinetic movements and turning behaviour in subchronic L-DOPA 6-hydroxydopamine-treated rats is influenced by the testing environment. Behav Brain Res (2006) 0.77
Behavioral, neurochemical, and electrophysiological changes in an early spontaneous mouse model of nigrostriatal degeneration. Neurotox Res (2010) 0.77
Subchronic caffeine administration sensitizes rats to the motor-activating effects of dopamine D(1) and D(2) receptor agonists. Psychopharmacology (Berl) (2002) 0.76
Microglial and astroglial activation by 3,4-methylenedioxymethamphetamine (MDMA) in mice depends on S(+) enantiomer and is associated with an increase in body temperature and motility. J Neurochem (2012) 0.76
MPTP-induced dopamine neuron degeneration and glia activation is potentiated in MDMA-pretreated mice. Mov Disord (2013) 0.76
Direct and indirect striatal efferent pathways are differentially influenced by low and high dyskinetic drugs: behavioural and biochemical evidence. Parkinsonism Relat Disord (2008) 0.76
Increase of dopamine D2(High) receptors in the striatum of rats sensitized to caffeine motor effects. Synapse (2008) 0.76
Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration? J Neurochem (2014) 0.76
Blockade of globus pallidus adenosine A(2A) receptors displays antiparkinsonian activity in 6-hydroxydopamine-lesioned rats treated with D(1) or D(2) dopamine receptor agonists. Synapse (2008) 0.76
Can dietary substances protect against Parkinson's disease? The case of caffeine. Exp Neurol (2010) 0.75
Subchronic intermittent caffeine administration to unilaterally 6-hydroxydopamine-lesioned rats sensitizes turning behaviour in response to dopamine D(1) but not D(2) receptor agonists. Behav Pharmacol (2005) 0.75
A(2A) Receptor Antagonism and Dyskinesia in Parkinson's Disease. Parkinsons Dis (2012) 0.75
Erratum to: MDMA administration during adolescence exacerbates MPTP-induced cognitive impairment and neuroinflammation in the hippocampus and prefrontal cortex. Psychopharmacology (Berl) (2015) 0.75
Multiple mechanisms of neurodegeneration and progression. Prog Neurobiol (2017) 0.75
Progression and Persistence of Neurotoxicity Induced by MDMA in Dopaminergic Regions of the Mouse Brain and Association with Noradrenergic, GABAergic, and Serotonergic Damage. Neurotox Res (2017) 0.75